While semaglutide activates only the GLP-1 receptor and tirzepatide targets both GLP-1 and GIP receptors, retatrutide activates all three metabolic hormone receptors: GLP-1, GIP, and glucagon
Other gastrointestinal effects of Wegovy that patients should be aware of include: Nausea and vomiting (particularly during dose escalation), which may affect the ability to take or retain oral medications Reduced appetite , which might influence the timing of medication taken with food Gastrointestinal discomfort , which could be confused with medication side effects If you experience persistent nausea whilst taking Wegovy, taking paracetamol with a small amount of food may help with tolerability
The following strategies can help ensure adequate fluid intake throughout treatment: Create a structured drinking schedule: Rather than relying on thirst alone, which may be diminished due to appetite suppression, set regular reminders to drink water
TNF-R1 signaling: A beautiful pathway
Contraindications and cautions include: Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (absolute contraindication) History of pancreatitis (relative contraindication